Artes Biotechnology  GmbH  
HomeAbout ARTESTechnologiesOfferProductsContact   
Recombinant Gene Expression   Vaccine Platform   Bio-similar Platform   Industrial Enzyme Platform    
  Arxula - Expression from yeast cells and fungal mycels | Artes Biotechnology GmbH

Arxula - Expression from yeast cells and fungal mycels | Artes Biotechnology GmbH
ARTES´ vaccine development platform (Metavax®)

Our chimeric duckHepB virus like particle approach (Metavax®) is best suited for the development of novel vaccines. Vaccines, produced with the WHO recommended Hansenula yeast technology in combination with the Metavax® platform, build a very economical approach to low-cost mass production of safe and effective vaccines.

Metavax® at a glance:

  • presentation of large antigens with more than 600 amino acids
  • presentation of complex, multimeric antigens
  • presentation of conformational epitopes
  • N- and C-terminal fusion to the duck S-antigen
  • stable co-integration of two or more targets
  • variable, controlled ratio of target antigen to S-antigen
  • stable production cell lines and respectively stable chimeric VLP´s
  • safe, low-cost production host already applied for vaccines
  • adjuvant-free formulation
  • stimulation of B- and T-cell specific immune answer
  • no risk of contaminating viruses
  • applicable for human and veterinary vaccines
 
 
Top of Page
  Copyright by Artes Biotechnology GmbH 2013